NCT03545789View on ClinicalTrials.gov

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 12, 2018

Primary Completion Date

February 6, 2020

Study Completion Date

February 6, 2020

Conditions
Healthy VolunteersAlzheimer DiseaseProgressive Supranuclear Palsy
Interventions
DRUG

[18F]MNI-958

Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.

Trial Locations (1)

06510

Invicro, New Haven

Sponsors

Lead Sponsor

Invicro
All Listed Sponsors
lead

Invicro

OTHER

NCT03545789 - Phase 1 Test-retest Evaluation of [18F]MNI-958 PET | Biotech Hunter | Biotech Hunter